

PHYSICIAN-FOCUSED PAYMENT MODEL TECHNICAL
ADVISORY COMMITTEE (PTAC)

+ + + + +

PUBLIC MEETING

+ + + + +

Virtual Meeting Via Webex

+ + + + +

TUESDAY, DECEMBER 8, 2020

PTAC MEMBERS PRESENT

JEFFREY BAILET, MD, Chair
PAUL N. CASALE, MD, MPH, Vice Chair
CARRIE H. COLLA, PhD
JAY S. FELDSTEIN, DO
LAURAN HARDIN, MSN, FAAN
JOSHUA M. LIAO, MD, MSc
TERRY (LEE) MILLS JR., MD, MMM
BRUCE STEINWALD, MBA
JENNIFER L. WILER, MD, MBA

PTAC MEMBERS IN PARTIAL ATTENDANCE

KAVITA K. PATEL, MD, MSHS

PTAC MEMBERS NOT IN ATTENDANCE

ANGELO SINOPOLI, MD

STAFF PRESENT

STELLA (STACE) MANDL, Designated Federal Officer
(DFO), Office of the Assistant Secretary
for Planning and Evaluation (ASPE)
AUDREY MCDOWELL, ASPE

A-G-E-N-D-A

Opening Remarks 3

PTAC Member Introductions.....10

Informing PTAC's Review of PFPMS¹ - Presentation
on Public Input Received
- Stace Mandl..... 15

Informing PTAC's Review of Telehealth and PFPMS -
Presentation on Public Input Received
- Audrey McDowell..... 29

Telehealth and Value-Based Care Transformation -
PCDT Presentation and Committee Discussion
- Jay Feldstein, DO..... 33

Instructions on the Report to the Secretary...96

Public Comments 102

Closing Remarks 109

Adjourn 110

1 Physician-Focused Payment Models

P-R-O-C-E-E-D-I-N-G-S

10:01 a.m.

1
2
3 * CHAIR BAILET: Welcome to the public
4 meeting of the Physician-Focused Payment Model
5 Technical Advisory Model Committee known as PTAC.
6 I'm Jeff Bailet, the Chair of PTAC. Because of
7 the coronavirus pandemic, we're holding this
8 meeting virtually rather than gathering in the
9 Great Hall of the Humphrey Building².

10 Our goal is for a seamless virtual
11 experience as close to in-person PTAC meeting as
12 possible. That said, we appreciate your
13 understanding in advance if any technical
14 challenges arise, such as sound delays or
15 background noise.

16 If you have any technical questions,
17 please email our contractor team at
18 PTACRegistration@norc.org. Again, that's
19 PTACRegistration@norc.org. If you've joined via
20 Webex, you can also message the meeting host with
21 any questions.

2 Hubert H. Humphrey Building

1 Many PTAC stakeholders are directly
2 involved in responding to the pandemic, and we
3 are thankful for your service to our country.

4 We want to thank providers, support
5 staff, caregivers, family members, and others who
6 are supporting patients during the pandemic. We
7 recognize that it's a privilege to have you
8 joining us today.

9 PTAC is committed as ever to having a
10 submitter-driven process. So, I remind you that
11 the Committee accepts proposals on a rolling
12 basis. Many potential future submitters may be
13 focused on the pandemic.

14 So, I remind anyone that you do not
15 need to worry about finishing your proposal to
16 meet a specific deadline.

17 The pandemic has highlighted many
18 challenges in our health care system, in addition
19 to prompting an unprecedented expansion of
20 telehealth.

21 At our September public meeting, we
22 debuted an additional mechanism for PTAC to

1 garner information that can inform our review of
2 proposals and raise awareness on key topics
3 related to value-based transformation.

4 The meeting included a discussion of
5 telehealth and Alternative Payment Models,
6 complete with panel discussions; information on
7 previous PTAC proposals that included telehealth
8 as a component; and a public comment period.

9 Following the September meeting, three
10 Committee members formed the Preliminary Comments
11 Development Team and commenced its review of the
12 discussion, key points raised at that time, as
13 well from the input that came in via our
14 telehealth Request for Input, or RFI.

15 Following careful consideration of all
16 of the meeting input and submitted information,
17 they developed a set of suggested comments on
18 recommendations, policy considerations, and
19 research questions that they will present to the
20 full Committee today.

21 In turn, the full Committee will
22 review what we learned in September and from the

1 RFI and discuss the comments and recommendations
2 we want to convey to the Secretary in a
3 synthesized report on telehealth. The theme-
4 based meeting discussions represent one of
5 several ways that PTAC continues to evolve to
6 meet a changing landscape.

7 We, as a Committee, routinely evaluate
8 our processes so that we remain well-positioned
9 to advise the Secretary on new ideas related to
10 payment models from the field, as is our charge,
11 and so that we can best activate and engage with
12 stakeholders to solicit such ideas and
13 information.

14 We're also called to serve those
15 stakeholders who seek to provide innovative ideas
16 that aim to address care delivery, quality, and
17 payment transformation.

18 To that end, we are exploring
19 opportunities through process changes or other
20 approaches that could expand and enhance our
21 ability to receive a broader array of proposals
22 and further engage with stakeholders.

1 We have a unique opportunity with
2 today's public meeting. We will discuss the
3 input we have received from a variety of
4 stakeholders over the year, in addition to
5 continuing our exploration of telehealth and
6 Alternative Payment Models.

7 As you may recall, in September we
8 convened two different panels of experts to
9 discuss telehealth and payment models: one panel
10 of submitters whose proposals to PTAC had
11 included telehealth and another of additional
12 experts representing several perspectives.

13 We also issued a Request for Input to
14 gather even more public input on the topic, and
15 we're pleased to receive many responses.

16 Three PTAC members who comprise the
17 Preliminary Comments Development Team have been
18 hard at work leveraging the holistic insights we
19 learned about and synthesizing them into
20 potential content for a report to the Secretary
21 on telehealth and payment models.

22 As I mentioned, they will present

1 their recommendations, and we will discuss how
2 their work will be incorporated in a report to
3 the Secretary. Then we'll wrap up the day with a
4 public comments period.

5 Before we begin our first
6 presentation, I have some announcements to make
7 about PTAC's work and its membership since our
8 last meeting in September.

9 At the public meeting, we deliberated
10 on two proposals: one submitted by the American
11 College of Physicians and the National Committee
12 for Quality Assurance and another submitted by
13 ASCO, the American Society of Clinical Oncology.

14 We have since published our reports to
15 the Secretary on these proposals, which you can
16 find online. Additionally, I'm excited to
17 welcome two new members of PTAC.

18 Dr. Carrie Colla is a Professor at the
19 Dartmouth Institute for Health Policy and
20 Clinical Practice, which is part of the Geisel
21 School of Medicine at Dartmouth College. Also,
22 Dr. Terry (Lee) Mills is the Senior Vice

1 President and Chief Medical Officer of
2 CommunityCare. Welcome.

3 They were appointed by the Government
4 Accountability Office in October and have been
5 diligently preparing to participate today.

6 I'm also pleased to announce that PTAC
7 has a new Vice Chair, Dr. Paul Casale. Paul is
8 one of the founding members of PTAC, and I look
9 forward to our partnership. Thank you, Paul, for
10 agreeing to take on these additional
11 responsibilities and service to the Committee.

12 I'd like to say a word about one of
13 our members who has reached her term limits on
14 the Committee since our last public meeting. Dr.
15 Grace Terrell, one of PTAC's founding members,
16 and contributed to the Committee's work in many
17 ways, including by serving as PTAC's Vice Chair
18 for the last two years.

19 We're grateful for her service to the
20 Committee, especially her vision in designing
21 these telehealth discussions, and we will miss
22 her greatly. I think I speak for all of my

1 fellow Committee members when I say that I look
2 forward to our paths crossing again.

3 * **PTAC Member Introductions**

4 And now, I would like PTAC members to
5 please introduce themselves. Please share your
6 name and your organization.

7 If you would like, feel free to share
8 a brief word about the experience you've had with
9 telehealth, our main topic for today. And
10 because of our meeting, because it's virtual,
11 I'll cue each of you and I'll start with myself.
12 I'm Jeff Bailet, the CEO of Altais, a physicians'
13 services organization. Paul.

14 VICE CHAIR CASALE: Hi, Jeff. Paul
15 Casale, a cardiologist. I lead Population Health
16 at New York-Presbyterian, Weill Cornell and
17 Columbia.

18 CHAIR BAILET: Carrie.

19 DR. COLLA: Carrie Colla. Jeff
20 already gave me a little bit of an introduction.
21 I'm an economist at the Dartmouth Institute for
22 Health Policy and Clinical Practice and have a

1 lot of experience with research and payment
2 models and participate in a lot of qualitative
3 and quantitative research about physicians'
4 practices.

5 My experience with telehealth has
6 mostly been on the patient side so I'll keep
7 comments mostly about what I've read in the
8 literature. Thanks.

9 CHAIR BAILET: Thanks, Carrie. Jay.

10 DR. FELDSTEIN: I'm Jay Feldstein.
11 I'm the President and CEO of Philadelphia College
12 of Osteopathic Medicine.

13 My experience with telehealth is that
14 in our set of primary care clinics when the
15 pandemic started, we had to pivot from in-person
16 to virtual in the span of a week, and it's been a
17 very interesting experience for both providers
18 and patients.

19 CHAIR BAILET: Thanks, Jay. Lauran.

20 MS. HARDIN: Good morning, I'm Lauran
21 Hardin, and I'm a Senior Advisor for the Camden
22 Coalition's National Center for Complex Health

1 and Social Needs. My experience with telehealth
2 over the last year has been working with sites
3 around the country who are building models for
4 complex populations, as well as to respond to the
5 social disaster from the pandemic, and telehealth
6 has been integral in all of those across the
7 board, across the community.

8 CHAIR BAILET: Thank you, Luran.
9 Josh.

10 DR. LIAO: Morning everyone, Josh Liao
11 here. I'm an internal medicine physician and the
12 Medical Director for Payment Strategy here at UW³
13 in Seattle.

14 My experience with telehealth has been
15 a dynamic one at our organization where so much
16 has changed. The volume of telehealth really
17 swelled in the earliest phases of the pandemic,
18 contracted, and as we swelled, and so, definitely
19 something that I'm still continuing to think
20 about and work on.

21 CHAIR BAILET: Thanks, Josh. Lee.

3 University of Washington

1 DR. MILLS: Good morning. Lee Mills.
2 I'm a family physician and Senior Vice President,
3 Chief Medical Officer at CommunityCare, a
4 regional-based provider and health plan in
5 Oklahoma.

6 My experience with telehealth has been
7 pretty deep both as a clinician using it in
8 patient care and in medical group operations and
9 administration, organizing networks and
10 physicians, and then on the health plan side
11 where we continue to support four or five
12 thousand telehealth visits per week among our
13 beneficiaries.

14 CHAIR BAILET: Thanks. Bruce.

15 MR. STEINWALD: Bruce Steinwald. I'm a
16 health economist here in Washington, D.C., and
17 I'm looking forward to my first telehealth visit
18 later this year.

19 CHAIR BAILET: Okay, Bruce. Jen.

20 DR. WILER: Good morning, I'm Jennifer
21 Wiler. I'm the Chief Quality Officer at UHealth

1 Denver⁴. I'm also a Professor of Emergency
2 Medicine for the University of Colorado. I'm a
3 co-founder of UHealth CARE Innovation Center
4 where we partner with digital health companies
5 where we can provide remote monitoring services.

6 And with regards to telehealth, I also
7 served for 11 years within the American Medical
8 Association RBRVS⁵ Updates Committee, where we
9 evaluated CPT⁶ codes related to telehealth
10 services.

11 And finally, as a provider, our health
12 system provides virtual care services for
13 patients within the Rocky Mountain Region, and I
14 do that myself as a provider.

15 CHAIR BAILET: Thanks, Jennifer. And
16 I don't know, Kavita? Kavita may not be, she may
17 not be yet joining us.

18 MS. AMERSON: Not yet.

19 CHAIR BAILET: Not hearing her, we're
20 going to go ahead. So, thank all of you. At

4 University of Colorado Health

5 Resource-Based Relative Value Scale

6 Current Procedural Terminology

1 this time, let's move to our initial
2 presentation. After our public meeting in June
3 of this year, we issued a Request for Input to
4 learn from stakeholders on how we might expand
5 our review of proposals.

6 All of the responses received are on
7 the ASPE PTAC website, and ASPE staff will
8 present some of the key point shortly. To my
9 colleagues on the Committee, after the
10 presentation, we will discuss our reactions and
11 some thoughts on how we could incorporate this
12 information to improve our existing processes.

13 * **Informing PTAC'S Review of PFPMS -**
14 **Presentation on Public Input Received**

15 I'm going to now turn it over to Stace
16 Mandl to present on what we learned from the
17 public responses to the RFI. Stace.

18 MS. MANDL: Thanks, Jeff. Good
19 morning everyone, and thank you everyone for
20 joining today. It's an honor to be here this
21 morning and report out on PTAC's June Request for
22 Input.

1 I'm Stace Mandl, and I serve as the
2 PTAC Staff Director here at ASPE. Next slide
3 please. This RFI was released in June, shortly
4 after the public meeting when PTAC announced its
5 vision.

6 The RFI aligns with PTAC's vision
7 statement and in particular its vision to
8 activate stakeholders and increase awareness of
9 issues related to payment and care delivery as
10 identified by frontline stakeholders. Next
11 slide.

12 This RFI included four questions that
13 were posted on ASPE's PTAC webpage. The first
14 question was what are the current challenges in
15 health care delivery and payment?

16 What is needed to push forward on
17 addressing care delivery issues and Alternative
18 Payment Models? Are there actual and potential
19 PFPMs⁷ that have not been addressed in proposals
20 submitted to PTAC so far?

21 What other factors would be important

7 Physician-focused payment models

1 to take into consideration to inform PTAC's
2 evaluation of proposals, including factors
3 related to engagement and adoption of models?

4 How might a proposed PFPM build on the
5 learnings from earlier models? And lastly, how
6 might care models that are included in the
7 proposals reviewed by PTAC be incorporated in
8 broader models like ACOs⁸ or Direct Contracting?
9 What factors would be important to take into
10 consideration such as barriers or facilitators
11 for adoption? Next slide.

12 PTAC received several responses to the
13 RFI, one of which represented several specialty
14 societies organized by the American College of
15 Physicians. Next slide, please.

16 Respondents submitted comments on
17 several topics regarding challenges in priority
18 areas, including coordination and integration of
19 care across services.

20 For example, comments included:
21 ``Fragmentation in health care increases, medical

8 Accountable Care Organizations

1 errors and poor outcomes, system waste and
2 inefficiencies, and dissatisfaction for all
3 parties. These effects are compounded when
4 patients have multiple clinicians involved in
5 their care."

6 Another comment was: "PTAC should give
7 priority consideration to models that support and
8 reward high-value interactions across settings."

9 And another commenter stated: "One of the central
10 considerations when it comes to existing models
11 is the lack of engagement between specialty and
12 primary care clinicians."

13 Other topics raised in comments
14 signaling priority areas for PTAC included
15 "Social determinants of health, proposals with
16 specific clinical focus areas, including primary
17 care or care for individuals with serious
18 illness, the needs of small or rural providers in
19 the context of APMs⁹, valuation and costs,
20 benchmarking and quality measurement, and
21 provider and patient attribution." Next slide,

9 Alternative Payment Models

1 please.

2 Respondents also flagged for PTAC to
3 take into consideration in their reviews
4 proposals that are for specialists; are about
5 serious illness; address the cost of homecare;
6 integrate non-physician providers; engage
7 community-based organizations; engage caregivers;
8 impact underserved and minority communities;
9 increase financial stability for providers; offer
10 up-front investments for small, rural, and
11 primary care providers; and balance quality with
12 savings to avoid stinting.

13 For example, one commenter expressed:
14 "There is an opportunity for new models to be
15 implemented or for existing models to expand in
16 such a way that bridges the chasm between primary
17 and specialty care and engages specialists in
18 more robust ways, including by promoting
19 specialist participation in the financial rewards
20 and the risks of the model." Next slide, please.

21 Stakeholders also flagged the
22 importance of stakeholder engagement in

1 activation. One commenter stated: "Signal that
2 PTAC is a viable path for clinicians to
3 meaningfully participate in value-based care
4 models that directly apply to the care in which
5 they provide."

6 Another commenter expressed:
7 "Providing scalable opportunities for specialists
8 not previously engaged in value-based care models
9 should be a priority for PTAC in HHS¹⁰ moving
10 forward."

11 These and other comments taken
12 together underscore the theme-based discussions
13 at the public meetings can help to raise
14 awareness of issues and priorities identified by
15 stakeholders.

16 And that such input, such as that
17 provided via this RFI and proposals themselves
18 can serve to highlight important issues and
19 specific needs in priority areas in value-based
20 care transformation. Next slide, please.

21 The comments are available on the ASPE

10 U.S. Department of Health and Human Services

1 PTAC website. The RFI and input received in
2 total is posted on our website.

3 And I want to thank you again for the
4 opportunity to report out on PTAC's June RFI and,
5 Jeff, thank you and the Committee for your
6 service, and at this point, I'll hand things back
7 over to you.

8 CHAIR BAILET: Thanks, Stace. We
9 appreciate you walking us through all of that
10 information, and we want to thank those who put
11 time and effort into sharing their perspectives
12 with us. I want our stakeholders to be assured
13 that we want to be responsive to what we've
14 heard.

15 So, we've already begun to work on
16 digesting the ideas you've raised and thinking
17 creatively about how we can incorporate them into
18 our processes.

19 For my colleagues on the Committee,
20 this is just one of multiple opportunities we'll
21 have today to discuss what our community of
22 stakeholders is telling us and how we can adjust

1 our processes accordingly.

2 I welcome thoughts from my fellow PTAC
3 members about the broad strokes of directions
4 we'd like to move in or we can save some of the
5 operational details for later.

6 But I'd like to get your thoughts on
7 any ideas that you have. So, I'm just going to
8 open it up to Committee members and, you know,
9 we'll have a discussion.

10 VICE CHAIR CASALE: Jeff, I'm happy to
11 start while others are thinking. This is Paul.
12 You know, I think there's several themes that
13 came through those comments but one, certainly
14 one of the consistent ones I just wanted to
15 highlight was around this primary, engagement of
16 primary care and specialists, and how to engage
17 specialists in the models. It seems to be an
18 ongoing challenge around the current models, and
19 even we have seen that as we've commented on
20 several other models that have been brought
21 previously before PTAC.

22 So, just wanted to flag that in

1 particular as something that was certainly
2 consistent through the comments that we heard
3 from, through this RFI.

4 CHAIR BAILET: I also think, Paul, to
5 that point, there's challenges where physicians
6 are in models, particular specialists already,
7 and if there's a new proposal, you know, how do
8 they figure out which camp they're in or which
9 models they're participating in? That's also
10 been a challenge for the specialists as well.
11 Carrie.

12 DR. COLLA: Another thing that struck
13 me reading through them was, in addition to what
14 Paul said about involvement of specialist is
15 about the fragmentation across both settings and
16 different types of clinicians.

17 I think nearly all of them really
18 focused on that and how you can create models
19 that work on fragmentations, not within a silo
20 but across settings and providers.

21 CHAIR BAILET: Thanks, Carrie. Anyone
22 else?

1 VICE CHAIR CASALE: Along these lines, this is
2 Paul again, I just wanted to again, when we think
3 about that care coordination, the engagement and
4 as Carrie said around fragmentation, you know,
5 not only, there's often again, just to flag sort
6 of on the clinical model has sort of been worked
7 out, but the financial model. So, how do the
8 different specialties and primary care, there's
9 often confusion around the sort of, how the
10 finances work and, Jeff, I guess to your point
11 about, you know, if the specialist is in one
12 model and then maybe in another one and trying to
13 understand how that all works, sometimes there's
14 quite a bit of confusion around how the finances
15 work around those things.

16 DR. LIAO: Hi, this is Josh. I would
17 just, you know, bringing together Carrie and
18 Paul's points about not just specialty and
19 primary care, not just phases of care but kind of
20 the interaction between the two, right.

21 That the coordination will look
22 perhaps different for primary and some specialty

1 care and outpatient setting and the acute setting
2 and the post-acute setting.

3 And thinking about those as distinct
4 and then kind of creating payment structures
5 around each of those or kind of working them
6 together, I think is, it's a critical piece.

7 MS. HARDIN: This is Lauran, and to
8 build on what Josh said, also the,
9 interprofessional cross-sector nature of the
10 coordination that's occurring now and how that's
11 shifting the way people are looking at payment.

12 So, in order to really have a high-
13 quality patient experience through the lens of
14 the person, it's involving integrating social
15 services, community-based organizations, and
16 other funding streams.

17 And I think that will be our challenge
18 going forward -- is what are those payment models
19 look like when we actually look at it through a
20 community lens and an equity lens?

21 DR. COLLA: Jeff.

22 CHAIR BAILET: Thanks, Lauran. Other

1 comments?

2 DR. COLLA: One other comment on a
3 little bit of a different topic is that a few of
4 the respondents also mentioned risk adjustment
5 and kind of the inability of risk adjustment to
6 keep up with these models, and thinking about new
7 ways to approach risk adjustment to make these
8 models work better.

9 CHAIR BAILET: Yes, I think that's a
10 good point, Carrie, and also there's, I don't
11 want to say disparities but there are significant
12 differences between the clinic settings.

13 We've also been working with the
14 stakeholders who are in rural or small practices
15 versus urban or academic centers. There are some
16 nuances there that have played through as it
17 relates to the robustness of the models.

18 DR. COLLA: Particularly around social
19 needs, I think we're just starting to get into
20 concrete methods of how to adjust for social
21 needs in particular and some of them mentioned
22 that.

1 CHAIR BAILLET: Right. Additionally, I
2 think it would be great to let the public know
3 that we are wanting to make sure that the
4 pipeline for proposal submissions continue.

5 And we understand that part of what
6 we're seeing as it relates to a little hiatus in
7 proposal submissions now, could be related and
8 probably somewhat related to COVID and everyone
9 hunkered down to address the pandemic.

10 We also want to make sure that we
11 don't stifle the innovation, which was the
12 premise for standing up the PTAC.

13 And so, we're working internally to
14 figure out, is there ways that we can sort of
15 engage with stakeholders to foster the ability
16 for them, for the stakeholder community to submit
17 models that may not have all of the attributes
18 that would be required under the Secretary's
19 criteria, but are strong enough in their
20 innovative ideas that we would still want to
21 consider them, and there'll be more to follow on
22 that as we internally are figuring out how that

1 could potentially shape up.

2 I just wanted to alert the public that
3 we are actively talking about that now because we
4 do want to make sure that folks out there have
5 the opportunity to submit their ideas and
6 innovations going forward.

7 Any other comments we want to make at
8 this point? All right. So, that was helpful.
9 We'll certainly discuss in more detail. We have
10 administrative meetings, the aspects that we are
11 seeing today in a later session this afternoon.

12 I'd like to wrap up and transition to
13 telehealth, that portion of our agenda, and we'll
14 begin by reviewing what we learned from our
15 various sources, including panelists and public
16 commenters at our September public meeting, an
17 environmental scan that was accomplished and also
18 a different RFI we released about telehealth.
19 Then we'll have a Committee discussion period to
20 sift through all of what we've learned to
21 identify the policy considerations and research
22 questions that we might include as comments to

1 the Secretary.

2 * **Informing PTAC'S Review of Telehealth**
3 **and PFPMS - Presentation on Public**
4 **Input Received**

5 So, let's start by learning what
6 stakeholders shared in response to our Request
7 for Input on telehealth and payment models.

8 Committee members, just as we did with
9 the previous presentation, I'd like us to discuss
10 any initial reactions you have, so please be
11 ready to share after Audrey gets done with her
12 presentation.

13 Audrey McDowell is a Program Analyst
14 and member of the ASPE staff team that supports
15 PTAC, and she'll present a synthesis of these
16 responses so, Audrey, please go ahead.

17 MS. MCDOWELL: Thanks, Jeff. As Jeff
18 stated, my name is Audrey McDowell, and I
19 appreciate the opportunity to review the
20 responses that were received to PTAC's Request
21 for Input on telehealth and physician-focused
22 payment models or PFPMS. Next slide.

1 Stakeholders submitted 18 PFPM
2 proposals to PTAC that included telehealth as a
3 component, and PTAC held a theme-based discussion
4 on telehealth in the context of APMs and PFPMs
5 during its September public meeting.

6 And then after the public meeting, the
7 Committee released an RFI on telehealth to gain
8 additional insights from stakeholders. Next
9 slide.

10 As discussed earlier, PTAC's release
11 of these RFIs is consistent with the Committee's
12 vision of providing a forum for encouraging
13 stakeholders to increase both awareness of
14 important payment and care delivery issues and
15 also, to develop important solutions to these
16 issues. Next slide.

17 This is an overview of some of the
18 topics that were addressed in the telehealth RFI,
19 ranging from best practices to performance
20 metrics, and beneficiary education needs. A full
21 list of the telehealth RFI questions can be found
22 in the appendix of this slide deck. Next slide.

1 This is a list of the nine respondents
2 to the telehealth RFI, which included five
3 associations, two other organizations, and two
4 individual physicians. And it's noteworthy that
5 four of the respondents were actually previous
6 PTAC proposal submitters. Next slide.

7 There was consistency between many of
8 the themes in the stakeholders' responses to the
9 telehealth RFI and the themes from the September
10 public meeting.

11 The respondents to the telehealth RFI
12 also provided additional insights regarding
13 several topics, including performance-related
14 metrics, monitoring and evaluation methods, and
15 beneficiary education needs.

16 Additionally, the telehealth RFI
17 responses also addressed some topics that were
18 not specifically included in the RFI. Next
19 slide.

20 The following are some excerpts from
21 some of the stakeholder responses relating to the
22 need for measures to precisely define which

1 aspect of telehealth is being measured when
2 considering the impact on cost, quality, and
3 experience of care.

4 The need for telehealth as another
5 site or modality to be held as another site or
6 modality, rather than type of care, to be held to
7 the same quality and safety standards as other
8 care settings, and potentially to adapt rather
9 than reinvent quality measures for telehealth.

10 And also, the need for robust
11 education to help beneficiaries understand how to
12 use telehealth. Next slide. Next slide.

13 Regarding next steps, the information
14 from the responses to the telehealth RFI will be
15 incorporated into today's discussion on
16 telehealth and value-based care transformation,
17 as well as the report to the Secretary, and also,
18 in subsequent PTAC environmental scans related to
19 future PFPM proposals that incorporate
20 telehealth. Next slide. As discussed earlier,
21 the Appendix includes the full text of the
22 questions from the telehealth RFI. Next slide.

1 All of the responses to the telehealth
2 RFI are available on the ASPE PTAC website and
3 that concludes this presentation. I will turn it
4 back over to Jeff.

5 CHAIR BAILLET: Thank you, Audrey.
6 That was helpful, and it was a great way to begin
7 the telehealth portion of today's meeting. And
8 of course, our thanks to those who shared those
9 insights with us.

10 Committee members, were there any
11 specific points from the RFI responses that you'd
12 like to discuss at this time before we move into
13 the actual Committee's work on the telehealth
14 initiative?

15 * **Telehealth and Value-Based Care**
16 **Transformation - PCDT Presentation and**
17 **Committee Discussion**

18 All right. Hearing none, I think
19 we'll just move right in then. As I mentioned
20 earlier, PTAC plans to release a report to the
21 Secretary synthesizing its comments and
22 recommendations from our deep dive into

1 telehealth and payment models.

2 As I noted earlier, the Preliminary
3 Comments Development Team, which is a new team
4 for PTAC, had focused on synthesizing what we've
5 learned at our September meeting and since then,
6 through the RFI.

7 They have created a set of slides with
8 potential comments that we could include in our
9 upcoming report, and we'll walk through it with
10 them today. As a quick disclaimer, their
11 findings do not necessarily represent the full
12 Committee's position, and they're not binding.

13 After their presentation, we'll
14 discuss their findings and the extent to which we
15 would like their recommendations to be part of
16 our final report.

17 At this time, I'd like to turn it over
18 to Jay Feldstein, the Lead of the Preliminary
19 Comments Development Team, who'll report out to
20 the full Committee the team's suggested comments.

21 At four separate points during his
22 presentation, Jay will review the suggested

1 comments for Committee deliberation. To stay on
2 track with the day's agenda, we should plan on
3 keeping our deliberations for each segment to
4 about 10 minutes.

5 I think we have maybe a little bit
6 more time, since we're a little ahead right now,
7 but needless to say we'll try and stay on track
8 and, Jay, please go ahead. You're on mute, sir.

9 DR. FELDSTEIN: That's better. Thank
10 you, Jeff. Good morning, everyone. This is our
11 report on our Preliminary Comments Development
12 Team findings on the role telehealth can play in
13 optimizing health care delivery in value-based
14 transformation in the context of Alternative
15 Payment Models and physician-focused payment
16 models.

17 I'd like to thank my other team
18 members, Carrie Colla and Luran Hardin, for
19 their hard work and dedication.

20 And also, to Audrey and Stace, to the
21 ASPE team, for really synthesizing a tremendous
22 amount of information that was relayed to us

1 during our September meeting. And I look forward
2 to sharing our information with you and to a
3 robust discussion. Next slide.

4 Today's overview, we'll talk about the
5 background, the Preliminary Comments
6 [Development] Team composition, review process,
7 an overview of key findings relating to
8 telehealth in the context of APMs and PFPMs, and
9 the key issues and potential comments identified
10 by the PCDT¹¹. Next slide.

11 On September 16th, PTAC held a theme-
12 based discussion on Telehealth in the Context of
13 Alternative Payment Models and Physician-Focused
14 Payment Models.

15 The goal was to provide PTAC with
16 current perspectives on the role telehealth can
17 play in optimizing health care delivery and
18 value-based transformation in the context of APMs
19 and PFPMs in order to further inform the
20 Committee's review of future proposals.

21 The telehealth session included a

11 Preliminary Comments Development Team

1 presentation on the 18 previous PTAC proposals
2 with a telehealth component, panel discussions
3 with six past submitters whose proposals included
4 a telehealth component and a diverse group of
5 subject matter experts, and public comments from
6 stakeholders.

7 Prior to the public meeting, an
8 environmental scan was prepared that provided
9 background information on telehealth, the role of
10 telehealth in the context of APMs and PFPMs, and
11 issues and opportunities associated with
12 optimizing telehealth in an APM.

13 After the public meeting, PTAC
14 released a Request for Input, an RFI on
15 telehealth and developed a supplement to the
16 environmental scan on telehealth. Next slide.

17 To prepare for today's discussion,
18 three PTAC members, our team, volunteered to
19 serve on the Preliminary Comments Development
20 Team and one of us serving as the lead. After
21 reviewing the available information, we prepared
22 a summary table and a presentation summarizing

1 its findings for the full PTAC.

2 Our findings are typically posted on
3 the PTAC website at least one week prior to
4 public deliberation by the full Committee. Our
5 findings are not binding on PTAC, and PTAC may
6 reach different conclusions from those contained
7 in our presentation.

8 The report to the Secretary will be
9 prepared based on the results of the full
10 Committee's deliberation, and this is our flow
11 diagram of our process and where we are today.
12 Next slide.

13 In terms of an overview of our key
14 findings relating to telehealth in the context of
15 APMs and PFPs, the following of the overview is:
16 there are many different definitions of
17 telehealth, whether it be virtual visits, audio
18 visits, telemonitoring; there are various types
19 of barriers that have affected telehealth use;
20 telehealth use increased during the public health
21 emergency; increased use of telehealth provides
22 opportunities to improve health care; some best

1 practices for optimizing the use of telehealth
2 services; how to address barriers affecting
3 beneficiaries' access to telehealth; the role of
4 APMs in optimizing the use of telehealth
5 services; and payment issues relating to
6 telehealth services. Next slide.

7 The importance of considering the
8 relevance of potential comments to APMs and
9 PFPMs. Many telehealth issues and potential
10 comments are broadly applicable to both value-
11 based context and traditional reimbursement
12 arrangements.

13 During the Committee's deliberations,
14 it will be important to highlight which topics
15 and comments are most important in the PFPM or
16 value-based context. Next slide.

17 We put our comments into distinct
18 categories. Category One focused on
19 infrastructure for both provider and beneficiary
20 needs. Category Two are barriers and enablers,
21 policies related to access and optimization, and
22 Category Three, payment issues, paying for

1 telehealth under physician-focused payment models
2 or Alternative Payment Models, and Category Four,
3 what research questions to address the gaps in
4 our knowledge. Next slide.

5 Category One, provider and beneficiary
6 needs. How do we avoid disparities? How do we
7 focus on vulnerable populations? What are the
8 provider needs? How do we address standards for
9 adoption and use?

10 And how do we address benchmarks and
11 variation in standards by setting? And how do we
12 understand provider and beneficiary costs? Next
13 slide.

14 What are our beneficiary needs, and
15 how do we avoid disparities? Our key
16 observations: virtual care can exacerbate
17 disparities in care for vulnerable populations,
18 whether it be underrepresented minorities or
19 those living at home with long-term support
20 service needs.

21 How do we address those without access
22 to devices, broadband, or comfort using

1 technology and who face a digital divide? And
2 then populations with physical and cognitive
3 impairments to using technologies have special
4 needs as well.

5 From a proposed comment perspective,
6 we need to consider sponsoring a report to
7 investigate or describe unintended consequences
8 associated with widespread adoption and the use
9 of telehealth that addresses the potential for
10 exacerbation of disparities in care for specific
11 populations due to the digital divide, cognitive
12 and physical impairments, and long-term support
13 services for those living in the community with
14 limited caregiver support. Next slide.

15 How do we focus really on vulnerable
16 populations? Aging or disabled populations with
17 long-term service needs and others residing in
18 the community with limited caregiver support are
19 socially isolated with unmet needs.

20 Visual and hearing impairments and
21 limited caregiver support present challenges to
22 usability. Cultural sensitivity, language

1 translation services, and attention to health
2 literacy are also needed. And addressing the
3 needs of these populations requires strategic
4 care planning to ensure access to adequate
5 virtual care.

6 We need to partner with a diverse
7 array of stakeholders, including providers and
8 those representing the beneficiary voice in the
9 development of standards for adopting telehealth
10 to address long-term service needs of community
11 dwelling populations; and to address the impact
12 of social isolation.

13 Consider further research on
14 unintended consequences of widespread use of
15 telehealth address disparities in care for
16 specific populations, including those with
17 impairments or those who require language
18 translation and culturally competent education.
19 Next slide.

20 How to address provider needs for
21 standards and adoption in use. Telehealth can
22 provide as needed access to interdisciplinary

1 providers-- social workers -- for patients, staff
2 in skilled nursing care facilities.

3 An APM could support a cultural shift
4 from using telehealth as an event, to providing
5 routine access. The rapid adoption of telehealth
6 has led to some providers to adopt new workflows
7 and approaches for determining the need for in-
8 person care.

9 The key strategies include enhancement
10 of team-based approaches and use of a telephone
11 or audio-only backup in case of technology
12 failure. Telehealth may exacerbate data silos if
13 we're not careful in integrating it with
14 electronic medical records.

15 From a proposed comment perspective,
16 in the context of APMs, considering developing
17 partnerships with a diverse array of stakeholders
18 -- including providers and those representing
19 beneficiary voices -- to support the development
20 of standards for telehealth adoption, including
21 workflow, service integration, team-based
22 approaches, shifting to a culture of routine

1 access, and determining when telephone or audio-
2 only access is appropriate and sometimes the only
3 technology available, and the interoperability of
4 data gathered in the context of telehealth, so we
5 do not create an additional silo in health care.
6 Next slide.

7 And how do we address provider needs
8 from a benchmark and variation in standards by
9 setting? Virtual services cannot fully
10 substitute for hands-on care. Payment parity may
11 be appropriate for insuring access to some
12 services but may introduce program integrity
13 concerns.

14 Current guardrails to support
15 appropriate protections may not be sufficient.
16 Additional guidelines, quality metrics, and
17 benchmarks may be needed, and different settings,
18 provider types, and clinical scenarios may
19 warrant different standards.

20 We need to consider partnering with a
21 diverse array of stakeholders to support the
22 development of standards for appropriate adoption

1 of telehealth by setting.

2 Modified clinical quality measures for
3 virtual versus in-person care, benchmarks using
4 patient satisfaction measures to convey a virtual
5 care to in-person care, and the use of analytic
6 technology to enforce program integrity rules.
7 Next slide.

8 How do we understand provider and
9 beneficiary cost? There's a lack of rigorous
10 methods for accounting for provider costs means
11 true cost of adoption is not known. Variation in
12 cost by geographic area and provider type are
13 also unknown.

14 And beneficiaries may also face costs
15 associated with devices and connectivity.
16 Appropriate APM payment mechanisms to cover these
17 costs require more exploration.

18 And in the context of APMs, we need to
19 consider exploring interest in partnerships again
20 with a diverse array of stakeholders to support
21 the development of accurate methods to
22 comprehensively account for costs of telehealth

1 adoption and use for different provider types.

2 And we need research on costs
3 associated with beneficiary access to broadband
4 connectivity, technologies, tablets, and
5 technical support needed to benefit from
6 telehealth. Next slide.

7 So at this time, we'd like for PTAC to
8 have a discussion of our suggested comments. In
9 the following two slides, we have summaries of
10 what we've just gone through. I'd open it up to
11 members of my team and also, Mr. Chairman, to
12 give it back to you for a full Committee PTAC
13 discussion.

14 So, if we could advance to the next
15 slide, which is a summary of what we've gone
16 through, that'll be a good place for us to start.
17 Thank you.

18 CHAIR BAILET: Thanks, Jay, and I'd
19 look to Carrie and Lauran if you guys wanted to
20 make any additional comments before the full
21 Committee weighs in.

22 MS. HARDIN: I think Jay covers this

1 well, Jeff, and I think one of the most important
2 issues we saw in the comments and around the
3 country is the importance of really integrating
4 diversity and equity in the way we look at
5 telehealth.

6 CHAIR BAILET: Okay. Thanks, Luran.
7 Nice job, Jay. We're going to open it up to the
8 full Committee. Bruce. You're on mute.

9 MR. STEINWALD: Thank you, Jeff.
10 Thank you, Jay. Can you hear me now?

11 CHAIR BAILET: Yes, we can.

12 MR. STEINWALD: Okay, good. I'm
13 referring back to your slide where you identified
14 program integrity as an issue, and I wanted to
15 comment on that a little bit.

16 In full disclosure, I spent 10 years
17 at the Government Accountability Office covering
18 health care spending and Medicare spending issues
19 in particular and have a heightened sensitivity
20 of how certain developments may have spending
21 implications that are concerning.

22 The advancement of telehealth,

1 especially in the context of the pandemic, is
2 terrific, but with rapid growth there comes the
3 potential for overuse and misuse, and I think we
4 need to be, looking ahead past the pandemic when
5 we have now an infrastructure installed for much
6 more telehealth in the health care system in
7 general.

8 And how we can make sure that that
9 infrastructure doesn't generate additional,
10 unnecessary spending, and one comment I would
11 make in that regard, and I know you're going to
12 get to this later, is building telehealth into
13 APMs and PFPMs in maybe one very competent way of
14 ensuring that these services are used
15 appropriately and don't create a real problem for
16 Medicare spending.

17 CHAIR BAILET: Thanks, Bruce. Any
18 other Committee members have comments to make at
19 this point? Carrie.

20 DR. COLLA: Just to really piggyback
21 on what Bruce said, and I think it's this tension
22 we're dealing with of wanting to create access

1 while wanting to think about program integrity.

2 And also, as someone who worries a lot
3 about health care spending and its implications
4 on both public and private budgets, I think we
5 also want to deeply consider situations in which
6 telehealth is substituting for existing care as
7 we saw at the height of the pandemic.

8 Whereas, research from before the
9 pandemic showed that a lot of telehealth services
10 were supplementing normal care, in which case
11 that would have a bigger implication for overall
12 Medicare spending.

13 And I think just in considerations to
14 make in that choice, although it is difficult to
15 determine that based on claims, and so in a fee-
16 for-service environment, it's more difficult to
17 try to parse out which of those scenarios you're
18 in.

19 And so, that's why an APM might be
20 more well suited to this, such as CMMI¹² is using
21 in existing APMs even before the pandemic. And

12 Center for Medicare & Medicaid Innovation

1 then also that research shows that the
2 effectiveness of telehealth in different clinical
3 scenarios varies.

4 And so, allowing providers to really
5 be able to make those determinations is also
6 appropriate in the context of APMs over which
7 clinical scenarios are more effective for use of
8 telehealth.

9 And finally, thinking about the
10 research in terms of telehealth in the context of
11 existing clinical relationships, ongoing
12 continuous care versus outsourced telehealth to
13 other types of providers, and how those might
14 differ in terms of the outcomes they might
15 produce.

16 CHAIR BAILET: Thank you, Carrie.
17 Other Committee comments?

18 DR. LIAO: This is Josh, by phone
19 here. I think the comments by Carrie I think are
20 relevant and building on that and what Bruce said
21 about, you know, APMs and PFPMs being maybe a
22 nice way of focusing on integrity.

1 I think the other perhaps
2 complementary point as I listened to all the
3 really critical and salient issues that Jay
4 outlined, some seemed that they will be
5 particularly relevant to APMS and PFPMS, perhaps
6 over others in terms of just implementing these
7 models.

8 And that may also vary by the model.
9 So, for instance, to Carrie's point about the
10 effectiveness in different clinical settings and
11 clinical kind of areas of care, you can imagine
12 that how we would design telehealth around a
13 primary care model may be very different than a
14 sub-specialty focused model anchored on
15 hospitalization versus kind of a more global
16 population-wide model.

17 So, I think there's a lot here and as
18 we think about well, what is the potential with
19 PFPMS, the kind of related question is what are
20 the issues that really drift up to the surface as
21 the most critical ones in each of these models
22 that I think would be good for us, the Committee,

1 to think about?

2 CHAIR BAILET: Thank you, Josh. Other
3 Committee members?

4 DR. COLLA: Just perhaps to slide us
5 into the barrier section. I think the balance
6 that we're thinking about is the balance between
7 flexibility and lower administrative complexity,
8 which was something we heard from the people who
9 wrote in with the program integrity goals that
10 Bruce brought up. And one of the things we've
11 seen in the pandemic is this relaxation of the
12 documentation and regulation around telehealth
13 that's allowed it to blossom and be used in a lot
14 of effective ways.

15 And so, thinking about how to balance
16 those two things in the context of APMs is
17 important.

18 CHAIR BAILET: Thanks, Carrie. I
19 would like to add one of the challenges that I
20 see as telehealth gets more embedded into
21 clinical care delivery is the point disparities,
22 particularly language, a language barrier.

1 And making sure that at the time of
2 the visit that the appropriate translation
3 services are available, and I think it's hit or
4 miss.

5 It's clumsy at times, and what we
6 don't want to do is have telehealth be built up
7 in a way that really creates tremendous burden
8 both on the patient and on the clinician.

9 So, I think that's going to have to be
10 well thought through and how payment for those
11 services gets baked into the model.

12 I hate to see where a translation
13 service is obviously needed and it's mandated,
14 but there's really no funding provided for it,
15 which I think has been a challenge in the past
16 for translation services.

17 So, I think that this an opportunity
18 to sort of rethink that, and I'm hoping that as
19 these models get incorporated with telehealth and
20 telehealth gets launched more broadly, so that
21 those considerations are thought about early on,
22 rather than creating requirements around

1 translation services and then the lack of
2 infrastructure support to ensure that those
3 services are delivered appropriately.

4 DR. COLLA: Piggybacking on the
5 disparity is also thinking about the types of
6 clinical providers who are able to do these types
7 of visits and including provider groups like
8 community health workers could also help with the
9 disparities issue.

10 CHAIR BAILET: Yes. And, Jay, I don't
11 know if we're going to get to it in other
12 segments but one of the things -- and if we are
13 going to cover it in another segment, I'll leave
14 it for then.

15 But I would like to spend a minute
16 talking about the challenge with incorporating
17 the data from a telehealth visit into the record
18 rather than, I think we were advised from one of
19 our stakeholder commenters in September that we
20 want to avoid creating another silo for data, you
21 know, to sort of sit in now the telehealth
22 modules, if you will, and rather than the

1 electronic health record. So I'll look to you,
2 Jay, if that's, if this is the right time to talk
3 about that or you're going to cover it in one of
4 your follow-on segments.

5 DR. FELDSTEIN: I think we cover it in
6 one of the follow-on segments, but there's no
7 reason we can't talk about it now because
8 regardless of what we go through, it has to be
9 addressed.

10 CHAIR BAILLET: Yes, I guess the point
11 I'm making is that it would really be, you know,
12 shame on us if we push out telehealth and it just
13 becomes another data sinkhole.

14 And it makes it even more burdensome
15 for both the patients and for the physicians and
16 all of the stakeholders to get access to this
17 information to maximize its potential.

18 I think it could potentially be
19 problematic if we don't really think about it and
20 incorporate, purposefully incorporate how to
21 avoid building out a system for telehealth that
22 would basically -- inadvertently probably --

1 create a sinkhole for data. That would be a
2 shame.

3 DR. FELDSTEIN: Yes, I think
4 especially when you look at freestanding
5 telehealth companies as compared to telehealth
6 being offered as an integrated -- as part of an
7 integrated delivery system -- where it's part of
8 the service model in that integrated delivery
9 system.

10 As opposed to freestanding telehealth
11 companies that individual patients can access on
12 an ad hoc basis. There are challenges in both of
13 those universes.

14 So, I think from a policy standpoint,
15 if we really don't address that upfront, we'll
16 end up building probably a potentially larger
17 silo than we've ever imagined.

18 VICE CHAIR CASALE: Yes, and I think
19 this also adds to the prior conversation we just
20 had around fragmentation of care and care
21 coordination being, you know, flagged as really
22 important as we think ahead around payment

1 models, you know, and telehealth has the
2 opportunity to help with that potentially.

3 But as you're pointing out, if it's,
4 where the data sits is going to certainly either
5 exacerbate that fragmentation or potentially
6 improve the coordination. So, being sure that
7 that's part of the thinking around, from a policy
8 point of view, I think is going to be important.

9 And on the disparities, you know, in
10 addition to the language and other issues, one of
11 the other challenges is just access to that
12 specialty care often. And so, telehealth may be
13 able to, you know, provide some additional
14 access. It would be important.

15 But again, it has to be in a way
16 that's integrated from a data point of view in
17 order to effectively coordinate that care.

18 CHAIR BAILET: Thanks, Paul. Before
19 we move on to the next segment, any other
20 comments on this portion? All right, Jay.

21 DR. FELDSTEIN: Okay.

22 CHAIR BAILET: I'll turn it back.

1 DR. FELDSTEIN: Thanks, Jeff. Our
2 second category is really, is barriers and
3 enablers to accessing virtual care. So, you
4 know, we need to have flexibility related to
5 coverage and payment in the context of APMs and
6 from an enabler's standpoint, consider research
7 when enabling patient monitoring and other
8 interventions as a form of telehealth. Next
9 slide.

10 So, in terms of barriers, there's
11 geographic limits, rural versus urban; state
12 licensing represents a barrier to access;
13 limitations on services covered, and site of care
14 for virtual care represent a barrier to access.
15 Currently there's been an easing of geographic
16 restrictions and expansion of covered virtual
17 services as due to our public health emergency.
18 Provider shortage pose a barrier to access to
19 care in urban and rural areas, especially around
20 substance use disorders.

21 And there's a complexity and
22 uncertainty in coverage for virtual care, which

1 unto themselves represent a potential barrier.
2 And telephone or audio-only may be a necessary
3 modality to ensure access for some populations.
4 So, in the context of telehealth and APMs, we
5 need to consider flexibilities related to
6 geography, site of service, covered services, and
7 provider state licensing. And where possible,
8 seek to provide greater certainty regarding
9 reimbursement and coverage policy for telehealth
10 under APMs during and following the PHE¹³. Next
11 slide.

12 Also, we need to look at chronic
13 disease populations. They often view being
14 symptomatic as part of their baseline or normal,
15 and they may not seek virtual care that can help
16 avoid hospitalizations or emergency department
17 visits or adverse health outcomes. And
18 telehealth which is not related to a virtual care
19 event, such as remote patient monitoring, can
20 provide proactive care, and these services are
21 not addressed through temporary [Section] 1135

13 Public health emergency

1 PHE waivers.

2 So, in the context of new and existing
3 APM models, we need to consider further research
4 that can assess the potential of adopting remote
5 patient monitoring and other forms of telehealth,
6 either new or existing models not related to the
7 existing temporary waivers during and after the
8 PHE. Next slide.

9 So, these really barriers and enablers
10 in terms of access and optimization, which we
11 kind of alluded to before, I think, you know,
12 warrant a lot of discussion. Not only from
13 geography, specialty, and just integration of all
14 these services that we talked about and not
15 building silos. So, Jeff, back to you.

16 CHAIR BAILLET: Thanks, Jay. I'll open
17 it up to the Committee. Well, maybe I'll jump
18 in, Jay, you know, when you talk about site of
19 service, I think about the traditional visit in
20 an exam room -- there's certain privacy and
21 security elements that are incorporated and
22 hardwired into that visit.

1 And I was thinking about, you know,
2 when you're in a situation where it's a
3 telehealth visit, the environment isn't
4 necessarily controlled. And so, I think it's
5 something that I'm sure is being looked at, but
6 what are the parameters around protecting patient
7 health information, making sure that the visit is
8 secure?

9 When you're in an exam room with a
10 patient, you know, obviously the patient knows
11 whether someone else is in the room like a scribe
12 or a nurse, assistant, et cetera. But that's not
13 the case in a telehealth visit so, I'm just
14 wondering have you guys, did you guys consider,
15 or that certainly didn't come up amongst the
16 stakeholders, and maybe that's something that we
17 can save for the research side of this
18 discussion.

19 But it is something that as it becomes
20 more ubiquitous in clinical delivery, I'm
21 wondering whether there needs to be some
22 purposeful design around telehealth in protecting

1 the security of the information in those visits.

2 What do you guys think about that?

3 DR. FELDSTEIN: Well, we looked at
4 that in terms of a research question, and we
5 address it somewhat when we talk about what are
6 the, you know, appropriate guardrails. But I
7 think we do need to be specific, you know, from a
8 HIPAA¹⁴ and cybersecurity standpoint as we move
9 forward. This is going to be, you know, another
10 data set that we're going to have to manage and
11 protect.

12 CHAIR BAILET: Right.

13 MS. HARDIN: That's a great --

14 CHAIR BAILET: And I don't -- go
15 ahead, I'm sorry. Go ahead.

16 MS. HARDIN: This is Lauran. That's a
17 great point, Jeff. And I think we didn't get
18 really deep into that, but it's so important to
19 think about privacy and confidentiality on both
20 sides of the technology. One of the interesting
21 things we've seen in the data across the country

14 Health Insurance Portability and Accountability Act

1 is there's actually been a very big uptake and
2 response to people actually attending behavioral
3 health telehealth visits as well as substance use
4 disorders. So, some of the services have
5 actually expanded access, but it also highlights
6 and exacerbates and makes even more important the
7 confidentiality question.

8 CHAIR BAILET: Right, yes. And again,
9 I think this is a, I'm just calling it out, we're
10 not going to solve it necessarily in our meeting
11 today. But I do think it needs to be highlighted
12 in our recommendation to the Secretary in our
13 final letter.

14 DR. LIAO: This is Josh. I just had
15 one other comment about the barriers. I was
16 struck by kind of, and not another thing we're
17 going to solve today. But I do think, you know,
18 telehealth -- we kind of group a number of things
19 together. What I heard from Jay and others is
20 that, you know, there's audio-only, audio-video,
21 and I think just an openness to kind of the idea
22 that things may prove in certain settings to be

1 more useful than others and being willing to kind
2 of focus on the ones that are most effective.

3 And so, the barriers will probably
4 look different perhaps across that as the
5 evidence comes out. And the other thing is, I
6 think relevant to our Committee, is this idea of
7 evaluation and the ability to be evaluated. And
8 so, there's that tension, at least in my mind,
9 around kind of there's a flexibility with which
10 people deploy these and then the ability to kind
11 of come to the other side and say did it work in
12 some way? And I don't have answer, but I think we
13 should keep that front and center when we think
14 about the barriers.

15 CHAIR BAILLET: Thanks, Josh. Carrie.

16 DR. COLLA: And building on that, in
17 the privacy and confidentiality issues, I think,
18 I mean, we're in the United States, we're focused
19 on Medicare, but we're really in a multi-payer
20 environment. And one of the problems we've seen
21 in terms of APM diffusion is also around standard
22 models across payers, and I think that is a

1 problem here too. When each payer has their own
2 set of rules and regulations around telehealth,
3 it really can inhibit expansion of these
4 services.

5 And so, thinking about the importance
6 of multi-payer alignment in these services and
7 standards in terms of confidentiality and privacy
8 in terms of the regulation. And then the other
9 thing in terms of barriers and facilitators that
10 struck me was really the importance of the state
11 laws about licensure and parity, and how
12 important they are in terms of the use of
13 telehealth across different states. This is pre-
14 pandemic -- now it's a little bit more similar.

15 CHAIR BAILLET: Yes, great point.

16 MS. HARDIN: And, Jeff, I would just
17 add one other point. This didn't necessarily
18 come up in our meeting or in the comments, but
19 what I've seen over the last few months is an
20 explosion of hospital-at-home. Partially to deal
21 with capacity and carry the COVID cases and
22 really make a proactive system, but that's really

1 going to affect number two and the technology and
2 monitoring that there are requests for -- really
3 deep payment. Because I think that shift is
4 going to be permanent.

5 CHAIR BAILET: Yes. I completely
6 agree, Lauran, and that's going to be amplified.

7 I don't see that going, I don't see that going
8 down. I see that becoming more common practice.

9 So, that's a great point.

10 VICE CHAIR CASALE: Yes, I wanted to -

11 -

12 CHAIR BAILET: Any other comments from
13 the Committee --

14 VICE CHAIR CASALE: -- yes.

15 CHAIR BAILET: -- yes, go ahead, Paul.

16 VICE CHAIR CASALE: I was going to
17 echo that point that Lauran just made. Also
18 saying the shift to sort of care at home models
19 and the explosion in remote patient monitoring
20 and anything from wearables to, you know, in
21 cardiology obviously, we've been monitoring, you

1 know, pacemakers and ICDs¹⁵ and other devices.
2 And understanding where it's a benefit and who's
3 actually looking at the data, what's the
4 infrastructure, and build a cost to monitor that
5 data as it comes in?

6 And then using that effectively,
7 whether, and then thinking through the models
8 where that might be, you know, particularly
9 beneficial. So, there's no question that I think
10 it is beyond the pandemic here to stay. I think
11 there's a lot, and I emphasize here around
12 research and assessment that needs to be done to
13 understand, you know, the effectiveness of each
14 of those modalities within remote patient
15 monitoring.

16 DR. WILER: I agree with Paul's
17 comments and wanted to add that I think under a
18 research agenda, that wasn't discussed here but
19 just to surface it, are how do we not increase
20 cost within the system? So, do we add human
21 capital resources to help with this remote

15 Implantable cardioverter-defibrillators

1 monitoring at home, or are there software
2 solutions like AI¹⁶ algorithms that are helping to
3 do this monitoring?

4 So, there needs to be some assessment
5 of how do we not add cost to the system but
6 actually, you know, improve value and ultimately
7 expand services without, and doing it in a safe
8 and effective way. And so, creating measurement
9 of that process is really important from a safety
10 and quality perspective. So, that could be
11 another aspect of the research agenda.

12 And the last comment I would make is
13 around this home-based care as a new care model
14 and being mindful of thinking about how do we
15 train the workforce to be able to do that. And
16 making sure we have alignment with, not in the
17 provider space or physician/provider space, GME¹⁷
18 programs that actually train our future
19 clinicians about how to deliver care in this way,
20 would also be a separate and distinct but
21 important research agenda.

16 Artificial intelligence

17 Graduate medical education

1 CHAIR BAILLET: Great. Great point. I
2 was just going to raise the issue of storage of
3 all of this information that we're expanding,
4 we're collecting, and more monitoring, to your
5 point, Paul. You know, monitoring ICD devices
6 and other devices that's going to continue to put
7 a burden on the storage and gets back to my
8 earlier point about security.

9 Where is this information going to
10 sit, and how are we going to store it in a way
11 that's going to be able to essentially expand as
12 the information expands so that it's still
13 accessible and it's still usable? And that's
14 something that we probably should incorporate in
15 our letter as well. Particularly security if
16 it's not -- right now there's very robust
17 security parameters around sort of the
18 traditional electronic health record, and the
19 visits, et cetera.

20 But I'm not so sure that's the case in
21 the telehealth world as it expands and other
22 vendors get into the space. Do they have the

1 same robustness in parameters around security and
2 access, et cetera? I know that when you work in
3 health systems, you know, you have auditing
4 abilities to actually look at who's accessed the
5 data and are they, do they have the appropriate
6 permission rights to do that and there are
7 recourses that can take place.

8 I'm not sure that all of that's being
9 built-in in the telehealth universe. So, that's
10 something to think about. All right. Any other
11 comments before I turn it back to Jay? All
12 right, Jay.

13 DR. FELDSTEIN: Okay. Let's move onto
14 Category Three, which is payment issues, you
15 know, and how do we, you know, to document our
16 emerging findings, how do we use APMs to enable
17 telehealth? And how do we leverage the insights
18 from our previous PTAC proposals? Next slide.

19 So, some of our key observations in
20 fact, were providers that are engaged in APMs,
21 were able to adapt quickly and pivot to virtual
22 care under the COVID-19 PHE. And that APM models

1 gave providers more flexibility sometimes through
2 prospective and risk adjusted payments, which we
3 had discussed early, to adopt to virtual care
4 modalities.

5 And that we need to consider
6 highlighting best practices and findings from
7 rapid adoption of telehealth among providers
8 involved in APMs across provider settings, and
9 clinical scenarios, stand-alones, substance use
10 disorders, or behavioral health, as well as the
11 usual source of care -- and this kind of just
12 dovetails to Josh's comments earlier. Next
13 slide.

14 Virtual care delivered under APMs can
15 be a tool to help ensure continuity of care,
16 avoid exposure and avoidable utilization, ED¹⁸ and
17 inpatient, especially in a PHE environment, and
18 support provider to provider coordination.
19 Flexibility afforded through prospective payments
20 and risk adjustment can support flexible adoption
21 of virtual care modalities. And additional

18 Emergency department

1 evidence is needed regarding the impact of
2 telehealth on cost, access, and quality for
3 various services.

4 We need to consider including
5 telehealth modalities across all APMs currently
6 in testing or development as tools for
7 facilitating access to care; optimizing care
8 delivery; reducing avoidable inpatient or ED
9 care; improving health outcomes; improving
10 provider coordination; and supporting provider
11 teaching, education, and collaboration. And we
12 should consider using ACOs or other models to
13 assist in testing the impact of telehealth on
14 cost, access, and quality for various services.
15 Next slide.

16 Now our 18 previous PTAC proposals
17 included telehealth as a component of their
18 models. Some of these proposals included
19 innovative care delivery models related to
20 providing remote assessment and education to
21 rural providers, relating to neurological
22 conditions, telemonitoring of patients with

1 chronic conditions, providing team-based care to
2 multiple skilled nursing facilities, ensuring
3 care coordination after discharge from EDs, and
4 maximizing primary care provider flexibility.

5 ACOs' shared savings could potentially
6 be used to support cost-saving telehealth
7 interventions. So by reviewing previous PTAC
8 proposals that included a telehealth component
9 and incorporate some of the telehealth related
10 elements from one or more of these proposals into
11 ACOs and other CMMI models that include
12 prospective payment and two-sided risk in order
13 to pilot test potential best practices and assess
14 their impact on health care costs and quality.
15 Next slide.

16 So that really, you know, when we
17 start to talk about payment issues, these were
18 the key ones that came to light both on the
19 discussions during our September 16th model, and
20 I also think we've got additional comments from
21 Lauran and Carrie on these as well.

22 MS. HARDIN: Thank you, Jay, this is

1 Lauran. I think one of the interesting things in
2 this arena is especially in behavioral health.
3 We've seen a tremendous drop in the no-show rate.
4 And it also brings up with behavioral health and
5 substance use disorder: what is a patient's usual
6 site of care? So, often with those services
7 they're seeing those providers many more times
8 than their primary care physician. So, it starts
9 to expand the dialogue about usual source of
10 care, how that care is funded, and how the data
11 is integrated.

12 CHAIR BAILET: Thanks, Lauran.
13 Carrie, do you have a comment? Maybe I saw your
14 hand go up, maybe it was a shadow, sorry about
15 that.

16 DR. COLLA: No, not right now.
17 Thanks, great job, Jay.

18 DR. FELDSTEIN: Jeff, or for
19 additional PTAC conversation and discussion.

20 CHAIR BAILET: All right. Payment,
21 this is a big issue. I'm happy to jump in but
22 would love my colleagues to go first if there's

1 any comments here. Well, we touched on it
2 earlier about, I think it was you, Jennifer,
3 talked about all payer, and I think really that's
4 going to be to some degree, the secret sauce here
5 is to get commercial payers to partner with
6 Medicare and create an intelligent framework for
7 payment.

8 I think that the variability in
9 payment now for telehealth services, and
10 particularly when the pandemic washes out, it has
11 the potential to be really problematic, and I
12 think this is the opportunity, and my preference
13 would be to get it right. And again, not saying
14 that there can't be any flexibility or variation,
15 but I do think it is the opportunity for the
16 commercial payers to really think about how to
17 pay for these services, what's incorporated,
18 what's not. Some of the items that we've already
19 touched on as it relates to elements like
20 disparities and translation services, et cetera.

21 Not to get, not to revisit that, but I
22 do think that the biggest barrier to uptake in

1 telehealth could be simply payment. And I think
2 it could be a huge, compelling accelerant to
3 further adoption. But it could it also be a huge
4 detractor, and specifically you think about
5 physicians and whether they're in small practices
6 or big systems, there's a lot of infrastructure
7 that has to get built to support telehealth. We
8 talked about some of those items today, storage,
9 security, et cetera. And it would be a shame to
10 build that infrastructure, which is a long-term
11 play and not have a payment methodology that
12 really supports it.

13 And I'm not saying a reckless payment
14 methodology. I think from a payer's perspective
15 that's always been the question mark -- is, you
16 know, how much control will they have on cost if
17 telehealth sort of just gets, you know, becomes a
18 free-swimming environment? And we're not
19 suggesting that by the way, but that's, I think,
20 one of the risks that the payers have been
21 resistant -- even Medicare, to some degree, has
22 been resistant on sort of -- and allowed them to

1 sort of govern the use of telehealth.

2 I think now is the time to understand
3 the value of telehealth, the real value that it
4 brings, avoiding emergency room visits, avoiding
5 all of the pain points for patients who have
6 limited opportunities for transportation. And
7 being able, from a provider's standpoint, to be
8 able to make those, get in those communications
9 with patients and their caregivers -- more of a
10 real time than trying to go through the
11 scheduling and appointment morass that some folks
12 have to struggle with.

13 So, if I could just back up, I really
14 do think payment is as much of a barrier as it is
15 an accelerant to telehealth adoption, and I think
16 we need to get it right as best we can.

17 VICE CHAIR CASALE: Yes, Jeff, hi,
18 this is Paul. Yes, I absolutely agree with that,
19 and thinking back in several of the proposals
20 that we reviewed that had sort of this baked in,
21 just a few comments around payment. I think one
22 of the challenges was in several of them, there

1 was the proposal for a prospective payment
2 related to, you know, building the infrastructure
3 and managing the telehealth.

4 But then when it came to the two-sided
5 risk, it was often, it was on the specialty side,
6 there was a reluctance to sort of think about
7 total cost of care. It was often around the care
8 related to that specific condition and reducing
9 either ED visits, et cetera, around that specific
10 condition. I think that's one opportunity to
11 explore further is, I think there needs to be
12 that prospective payment for all the reasons
13 we've talked about to build the infrastructure
14 and build, you know, the integration within the
15 system so that it is coordinated and not
16 fragmented. But then tied to, you know, value
17 world to this, to a two-sided sort of total cost
18 of care and think how that, more broadly how to
19 do that. Again, with the challenges of engaging
20 specific specialties but within that, I think it
21 spans that whole discussion around fragmentation
22 of care and care coordination -- and patients

1 don't just have one condition -- in order to
2 really build a platform that will work.

3 CHAIR BAILET: Thanks, Paul. That's
4 helpful. Any other --

5 DR. WILER: I want to agree with your
6 --

7 CHAIR BAILET: Go ahead, Jen.

8 DR. WILER: -- Yes, this is Jennifer. Yes, I want
9 to agree with the comments and just call out that
10 currently there's a perverse incentive with our
11 payment system that encourages care to be
12 delivered on site so, both the technical
13 component and the professional component. And in
14 organizations, you know, where there is
15 potentially not alignment, so, two parties
16 involved in care, which is, you know, the process
17 or relationship for many current, you know,
18 health systems and provider groups, there is
19 financial disincentive to not have facility-based
20 care. And so, I think exactly to your point, not
21 only the comments around, you know, multi-payer
22 but site of service is also something to be

1 considered. And then your comments, I just want
2 to reemphasize, around payment structure are
3 particularly important. And so, we've got other
4 payment models and programs == Meaningful Use is
5 obviously one that comes to mind -- where there
6 was acknowledgement that there's a big upfront
7 infrastructure cost that's required, and then
8 there was an alignment of incenting the
9 development of basic infrastructure to get
10 everyone sort of to jump from curve A to curve B
11 around a new care model and delivery model. And
12 so, I think the thought has to go to, and maybe
13 if this prospective payment, which is right what
14 we've seen a lot of stakeholders recommend in the
15 models that we've seen going forward.

16 But that has to be addressed because I
17 agree -- the payment model is what will keep from
18 developing a patient-centered care model, which
19 COVID has clearly shown that virtual care
20 services are a patient-centered care model.

21 CHAIR BAILLET: Yes. Thanks, Jennifer.

22 Any other comments --

1 MS. HARDIN: And then just to build on
2 --

3 CHAIR BAILET: Lauran, go ahead.

4 MS. HARDIN: This is Lauran. Just to
5 build on what Jennifer said. And so, the
6 dialogue also has been loud and advanced around
7 who actually gets paid for the telehealth visit.
8 So, as the care has rapidly disseminated into the
9 community and the home, social workers, nurses,
10 pharmacists, community health workers. There's
11 inter-professional care and really determining
12 who's best to do the visit and how does that fit
13 in the payment model total cost of care. And the
14 APMs help, but that question isn't going to go
15 away. If we look at it through the patient's
16 eyes about what they need and how do we
17 efficiently and effectively deploy the
18 technology?

19 CHAIR BAILET: Good point.

20 VICE CHAIR CASALE: And just adding on
21 to Jennifer's point about the, you know, the
22 payment differential. There's also payment

1 differential in the in-person visit where there's
2 often other ancillary services that are provided,
3 which provide additional payment into the system,
4 which is not there in a telehealth visit. So,
5 you know, again, just highlights some of these
6 differentials on payment between virtual and in-
7 person.

8 CHAIR BAILET: Thanks, Paul. Jay, we
9 may toss it back to you for research.

10 DR. FELDSTEIN: Okay. All right, next
11 slide. Well as with any robust discussion, we
12 often end up with more questions than answers,
13 and telehealth is no different. So, we've got a
14 fair amount of research opportunities and
15 questions based on infrastructure, beneficiary
16 and provider needs, standards for adoption, and
17 barriers and payment issues. So, we'll get right
18 into it. Next slide.

19 Consider sponsoring a report on
20 unintended consequences associated with
21 widespread adoption and use of telehealth that
22 addresses the exacerbation of disparities in care

1 for specific populations due to the digital
2 divide, cognitive and physical impairments, LTSS¹⁹
3 needs, and for those living in the community with
4 limited caregiver support.

5 Now how can we see the needs of these
6 populations be addressed in the context of
7 telehealth and APMs, and what features of an APM
8 will or will not facilitate helping these
9 populations benefit from access to telehealth?
10 Next slide.

11 Consider research on unintended
12 consequences of widespread telehealth use on
13 populations, including those with impairments or
14 those who require language translation and
15 culturally competent education. How can the
16 needs of these populations be addressed? What
17 features of an APM will or will not facilitate
18 helping these populations benefit from access to
19 telehealth? Next.

20 In the context of APMs, you know, what
21 types of partnerships with the diverse array of

19 Long-term services and supports

1 stakeholders, including providers and those
2 representing beneficiaries, support the
3 development of standards for telehealth adoption,
4 including workflow, service integration, team-
5 based approaches, shifting to a culture of
6 routine access, and interoperability of data
7 gathered in the context of telehealth? And what
8 is known about the standards of care, quality,
9 measurement, safety, and appropriateness in the
10 context of virtual versus in-person care? And
11 what are the best approaches for determining
12 services where there should be payment parity
13 between in-person and virtual care?

14 And how do we account for differences
15 in the care environment and incentives inherent
16 in virtual versus in-person care while also
17 maintaining simplicity and flexibility? Which
18 telehealth interventions are different
19 modalities/settings rather than a new type of
20 service, and are there program integrity
21 challenges associated with telehealth? Next
22 slide.

1 In the context of APMs, explore
2 research on costs associated with beneficiary
3 access to broadband connectivity, and
4 technologies, and technical support needed to
5 benefit from telehealth. How, if at all, should
6 APMs incorporate cost of implementation and
7 effective use of telehealth into their payment
8 design? How do different APM payment designs
9 facilitate or create barriers to effective
10 adoption and use of telehealth? And what
11 supports do beneficiaries receiving care through
12 APMs need to most effectively benefit from
13 telehealth? And how does beneficiary
14 satisfaction vary for specific services delivered
15 virtually versus in-person? Next slide.

16 In the context of new and existing
17 APMs, consider further research that could assess
18 the potential of adopting remote patient
19 monitoring and other forms of telehealth not
20 related to existing temporary waivers during or
21 after the PHE. And how does the role of
22 telehealth vary if the intervention is a

1 substitute for in-person care versus a complement
2 or supplement to in-person care? And how should
3 coverage and reimbursement rules vary for these
4 different forms of telehealth? Next slide.

5 And consider highlighting the best
6 practices and findings from rapid adoption of
7 telehealth among providers involved in APMs
8 across provider settings and clinical scenarios,
9 whether standalone substance use disorder,
10 behavioral health, as well as usual source of
11 care. And what are the reasons for and against
12 the inclusion of telehealth in different types of
13 payment models? What are the best approaches to
14 understanding the true cost of adopting different
15 telehealth modalities? And what are the models
16 of payment that will make these financial
17 investments feasible? Next slide.

18 So, these are a lot of questions for
19 us to take up, and I'm sure there's more that
20 will come out of our active discussion of these
21 areas. So, Jeff, I'll kick it back to you for our
22 last go-around here.

1 CHAIR BAILET: All right, Jay, nice
2 job. So, maybe Lauran, Carrie, you guys were
3 Jay's partners in this, did you guys have any
4 specific comments that you haven't already made,
5 relative to this last item around research
6 questions and gaps?

7 DR. COLLA: Just generally in terms of
8 like silver linings of the pandemic, what an
9 opportunity we have to learn about telehealth
10 based on what's happened in the last nine months.

11 So, I'm very interested to see, I think we'll
12 know a lot more in the next year about telehealth
13 than we do now.

14 CHAIR BAILET: Great.

15 MS. HARDIN: Agree with Carrie, and it
16 was well covered by Jay.

17 CHAIR BAILET: Super. Bruce.

18 MR. STEINWALD: I guess I'm thinking
19 of the pre-COVID world and how much do we already
20 know. I accept that we'll know a lot more from
21 the COVID experience, but let's say how
22 integrated delivery systems have used telehealth

1 versus how that contrasts with how telehealth is
2 rolled out in uncontrolled fee-for-service
3 system. Do we have much information about that
4 at present?

5 CHAIR BAILET: Anyone? Jay?

6 DR. FELDSTEIN: I don't know the
7 answer to that question. I think we know the
8 volumes have increased so dramatically that I
9 think, you know, most things operated at a much
10 lower volume pre-pandemic. So I don't think
11 necessarily a lot of attention was paid to it.
12 But obviously I think with the tremendous
13 increase in volume and utilization, we're going
14 to get a lot more answers in a lot faster time
15 frame.

16 MS. HARDIN: And, Bruce, I think there
17 was two drivers, so it's difficult to
18 differentiate where it grew. So, people in APMs
19 were really driven to control costs, and so
20 rapidly building that into their service was
21 really important. People who lost fee-for-
22 service revenue from the lack of in-person visits

1 were equally driven to build it out very quickly
2 so, I've seen a pretty broad swath growth across
3 the country in both buckets.

4 MR. STEINWALD: Be patient is the
5 answer, I guess.

6 CHAIR BAILET: Jay, I wanted to maybe
7 just pivot a little bit, but it is still in the
8 research category and that is related to, you
9 know, education of medical students and residents
10 on telehealth. You know, we have a very well and
11 very thoughtfully designed system to train for
12 medical education clinical staff. It's not just
13 physicians and medical students but also all of
14 the folks, all of the stakeholders that are in
15 the pipeline for care delivery.

16 But when it comes to telehealth, I'm
17 sure that there are opportunities for
18 standardization. That was something that you
19 raised earlier and education and also, some of
20 the parameters around signing off. If residents
21 and students are involved in telehealth visits,
22 you know, how do we ensure that they're conducted

1 appropriately, that there's clinical oversight
2 that's appropriate and all of that sort of
3 factored in?

4 And then, how to charge for those
5 particular services? Those are all complications
6 that we struggle with as it relates to education
7 in a traditional practice setting, and I think
8 telehealth just adds another layer of complexity.

9 DR. FELDSTEIN: It definitely does,
10 and the answer to your question is yes, yes, yes,
11 and yes. In fact, you know, we're trying now as
12 we rotate students through outpatient primary
13 care centers, as part of their experience they're
14 with their attending, and they're now doing
15 virtual visits as opposed to in-person visits.
16 And, you know, we're kind of taking them through
17 the logistics, you know, of how do you
18 operationalize it, what's a visit look like, you
19 know, but again, building on the foundation of
20 in-person first.

21 But a lot of medical, all medical
22 schools had to switch to a virtual environment

1 for, you know, traditional first and second
2 years, and the third year, clinical experience,
3 many medical schools had to go to virtual for the
4 third year. Because when the pandemic first
5 started, the hospitals were short on PPE,²⁰ and
6 they didn't really know how to handle it. So, a
7 lot of third year medical students were kind of
8 kicked out of the clinical setting from March to
9 about July.

10 And all medical schools had to adapt
11 to a virtual environment. So, it's kind of part
12 of the process now, and we're trying to figure
13 out, you know, how do we put the standards around
14 it from an educational standpoint? And to
15 Jennifer's comment earlier, I mean, the whole
16 future of GME is going to be altered as more and
17 more care is delivered out of the hospital. I
18 mean, the hospitals are traditionally the
19 delivery of graduate medical education from a
20 residency standpoint.

21 But as more and more care is in the

20 Personal protective equipment

1 home or various settings, how do we address that
2 from a residency training perspective and a
3 funding perspective? So, you know, there's
4 tremendous opportunity, but there's also
5 tremendous challenges that are before us.

6 CHAIR BAILET: Agreed.

7 MS. HARDIN: I think, Jay, and, Jeff,
8 another competency too is how to maximize
9 efficiency in the visit and inter-professional
10 integrated care. So, I've watched sites around
11 the country -- how they organize that visit and
12 integrate different disciplines, and how they're
13 doing it well. That will become even more
14 important in GME as well.

15 CHAIR BAILET: Thank you, Luran.

16 VICE CHAIR CASALE: And, Jeff, this is
17 Paul. This is maybe a tangential comment, but
18 I'm thinking about the Cures Act and the move to
19 greater transparency around notes, and so you can
20 imagine going forward in this world where the
21 notes are now, you know, the encounters will

1 create notes that are, patients will have access
2 to. And so, it'll be another impetus to thinking
3 how best to coordinate care as well.

4 CHAIR BAILET: Yes.

5 DR. FELDSTEIN: You know, the only
6 thing I would add, Jeff, is I think from a
7 research perspective, we really need to
8 incorporate what you brought up earlier in terms
9 of cybersecurity and data storage. And how to
10 protect this arena as it just, you know, grows
11 exponentially over the next two to three years.

12 CHAIR BAILET: Yes. So, we'll
13 definitely bookmark that. I thought maybe where
14 you were going to go, Jay, is the outcomes, you
15 know, how do we measure -- there needs to be some
16 standardized approaches to measure outcomes of
17 the effectiveness of telehealth on all of the
18 disease states.

19 There's a lot we don't know about,
20 about how effective telehealth is. We have some
21 good ideas in some areas, but then there are
22 long-term, you know, because of its uptake in the

1 last year, there's some long-term outcomes that
2 are still unclear.

3 And I think that that needs to, I'm
4 sure it's already being looked at, how effective
5 telehealth can be. Not only on the cost side but
6 also on driving quality results and reaching a
7 lot more folks. So, I think there's a lot of
8 research that's going to come out to really
9 explore outcomes over time.

10 DR. FELDSTEIN: Agreed.

11 DR. LIAO: This is Josh. I would just
12 build on Jeff's point and say that I think, you
13 know, as I reflect on what Jay was sharing about
14 how students and trainees are, you know, they're
15 having to kind of implement and learn these kind
16 of tele-visits. It strikes me that even before,
17 maybe in the surge related to the pandemic, that
18 there was variation in how different attendings
19 and clinicians delivered care, make that double,
20 triply so in the world of telehealth.

21 And so, I think without those
22 outcomes, Jeff, it's very hard to, I think for

1 learners to say is this just variation between,
2 you know, supervisor A and B, or is their outcome
3 to say, it quote, ought to be done that way. I
4 think that's going to be really critical if we're
5 serious about this research thing that we've been
6 talking about for the last 10 minutes.

7 CHAIR BAILET: Well, I think we should
8 be serious about it. Reason is the cost. I
9 mean, the expanse of a use of telehealth going
10 forward and even baking it in to payment models,
11 we need to know how best to deploy it to maximize
12 its potential and effectiveness.

13 So, that's definitely something that
14 I'm hoping we as a, you know, a system, a health
15 care system, figure out sooner rather than later.
16 Getting underneath outcomes has historically been
17 one of the foibles for our health care system and
18 so, I hope that it doesn't take as long on the
19 telehealth side as it has for traditional
20 practice.

21 VICE CHAIR CASALE: But I think we
22 have to also recognize, it's often not a direct

1 line between, you know, like a telehealth and an
2 outcome, right. Just like, you know, we know care
3 management is good but, you know, the direct line
4 between care management and outcomes, for years,
5 lots of research is mixed. So, it's going to be
6 difficult. But to reemphasize the cost piece and
7 the payment piece and how to tie that to maybe
8 more global outcome, I think we would require
9 more research and also, thinking about how to get
10 there.

11 CHAIR BAILET: Agreed. So, Jay,
12 Carrie, Lauran, really, really nice job. You
13 guys took in a tremendous amount of information,
14 had to distill quite a bit. And I appreciate the
15 fact that you've been able to present it to us to
16 spark the conversation that we just had that's
17 going to help us provide insights to the
18 Secretary in a way that hopefully will be very
19 valuable.

20 * **Instructions on the Report to the**
21 **Secretary**

22 Before we wrap up this section, I'd

1 like to ask Audrey, who's been listening intently
2 to our comments, if she could provide a brief
3 summary on some of the key points of our
4 discussion before we close out this section and
5 move on to the public comment section of our
6 public meeting today. Audrey. You might be on
7 mute, Audrey.

8 MS. MCDOWELL: Yes, sorry about that,
9 I had to unmute myself. So, I'm going to give
10 you a summary of what I heard, and this will
11 hopefully provide a basis for the information
12 that will be included in the report to the
13 Secretary. So, in terms of overall comments, it
14 sounds like the Committee believes that
15 telehealth, which includes a variety of different
16 services and modalities, can be an important and
17 effective tool for optimizing the delivery of
18 health care.

19 And also, that the increased use of
20 telehealth during the public health emergency
21 provides an important opportunity that can be
22 leveraged to hopefully increase the role of

1 telehealth and the delivery of value-based health
2 care where appropriate. With regard to the
3 challenges that need to be addressed in the
4 context of telehealth, there are a number of
5 challenges that the Committee has identified.

6 These range from barriers that have
7 affected beneficiaries' access to and ability to
8 use technology relating to telehealth; issues
9 specifically relating to vulnerable populations;
10 the need to develop standards and best practices
11 and quality measures for telehealth; the
12 importance of understanding the actual cost of
13 providing telehealth services, which is important
14 for being able to develop appropriate payments;
15 the need to, as well, address issues related to
16 coverage of telehealth such as which providers
17 should be covered; and issues related to site of
18 service and things of that nature.

19 Additionally, challenges that were
20 raised in the discussion also include the
21 tensions between increasing access and program
22 integrity concerns; determining the efficacy of

1 telehealth across services; also, the balance
2 between providing flexibility and administrative
3 complexity; and also there was a lot of
4 discussion about the upfront and infrastructure
5 cost related to telehealth and the variability in
6 payment.

7 So, in addition to the specific
8 comments that were included in the PCDT's
9 presentation, the report to the Secretary will
10 synthesize specific comments that were made as
11 part of this discussion. And in particular, the
12 Committee members discussed the potential role
13 that APMs with prospective payment mechanisms can
14 play in giving providers flexibility to use
15 telehealth effectively.

16 Also, testing the impact of telehealth
17 on cost, access, and quality for various services
18 and ensuring that telehealth is not overused. We
19 also heard discussion about the importance of
20 understanding which issues may be more relevant
21 for different kinds of models in the context of
22 APMs, such as primary care versus specialty

1 models.

2 The importance of addressing
3 disparities, including disparities related to
4 language, and ensuring that the cost of
5 addressing these disparities such as translation
6 services are included in the payment up front.

7 Additionally, discussion around the
8 types of providers that should be providing
9 telehealth services. One example was mentioning
10 perhaps community health workers. The importance
11 of improving care coordination, avoiding
12 fragmentation of care, and avoiding creating
13 another data silo related to telehealth. The
14 importance of protecting patient health
15 information. A lot of discussion around that.
16 The importance of evaluating which modalities are
17 most effective in addressing some of the specific
18 barriers that have been identified.

19 Implications of the increase in the
20 use of hospital-at-home models and remote patient
21 monitoring. And the need for research on
22 effectiveness and strategies for not increasing

1 cost with the use of these services.
2 Additionally, discussion around developing
3 appropriate payment models for telehealth and
4 reducing variability across payers. And finally,
5 the importance of getting information on
6 telehealth outcomes, which also has implications
7 for cost of these services.

8 So those are some of the major themes,
9 but staff will also be reviewing the transcript
10 and incorporating all of the, you know, the rich
11 discussion that we heard during this
12 deliberation. I think you're on --

13 DR. FELDSTEIN: Jeff, you're on mute.

14 CHAIR BAILET: Okay, thanks, Audrey,
15 for that great summary. I'm glad you're able to
16 keep up with us. That was very helpful.
17 Appreciate all your support. We are going to
18 close out this session. Any final comments from
19 the Committee before we move on to the public
20 comment section of our meeting today?

21 DR. COLLA: No. I just wanted to say
22 thanks, Audrey, for getting that all down and

1 also for all of the work by ASPE and NORC leading
2 up to this. Jay, you did a great job presenting
3 it, and they did a great job coalescing it, thank
4 you.

5 MS. HARDIN: Agreed.

6 CHAIR BAILET: Completely agree,
7 wholeheartedly.

8 DR. FELDSTEIN: Thanks, everybody.

9 * **Public Comments**

10 CHAIR BAILET: You're a rock star,
11 Jay. So, we're going to move into the public
12 comment section. We have three folks signed up.
13 They each have three minutes. I'm going to go
14 ahead and introduce them, and the lines will be
15 open. We're going to start with a former PTAC
16 member, Harold Miller, who's the President and
17 CEO for the Center for Healthcare Quality and
18 Payment Reform. Welcome, Harold.

19 MR. MILLER: Thanks, Jeff, it's nice
20 to with you and hello, everybody. Congress
21 created PTAC for one very specific reason, to
22 increase the number of physician-focused payment

1 models in the Medicare program. PTAC has failed
2 to achieve that goal since none of the models
3 recommended by PTAC have been implemented
4 by CMS²¹. In most respects, the process
5 established by Congress worked extremely well.
6 Dozens of physicians in specialty societies
7 developed excellent proposals for payment
8 models that would improve the quality of care
9 and reduce Medicare spending, and PTAC
10 recommended 17 of those models for testing or
11 implementation. However, despite that huge
12 investment of time and effort by both the
13 applicants and the members of PTAC, CMS has
14 refused to implement any of the models that PTAC
15 recommended. This is not because CMS found better
16 ways to implement physician-focused payment
17 models. Five years after the passage of MACRA,²²
18 most physicians in the country are still unable
19 to participate in an Alternative Payment Model.
20 This includes both primary care physicians and
21 specialists. Moreover, the APMs that CMS
has implemented have been failures. None of
the

21 Centers for Medicare & Medicaid Services

22 Medicare Access and CHIP Reauthorization Act of 2015

1 Innovation Center models have resulted in net
2 savings, and the Medicare Shared Savings Program
3 has only managed to reduce spending by less than
4 one percent after seven years of trying.

5 A major reason the CMS APMs have
6 failed is because they are not physician-focused.
7 Unlike the models PTAC has recommended, CMS APMs
8 have not addressed the problems in the fee-for-
9 service system that prevents the delivery of
10 high-value care. Increasing the level of
11 financial risk in bad models will make them worse
12 not better.

13 Because it is now clear that CMS
14 ignores all recommendations from PTAC, no one is
15 even submitting proposals to PTAC anymore. It
16 has been more than nine months since PTAC
17 received its last proposal. The people who
18 should be most concerned about this are the
19 members of PTAC, yet you have remained silent
20 about the problem. Over the course of a two-hour
21 meeting this morning, there has been no
22 discussion about the failure to implement PTAC

1 recommendations or what should be done to address
2 it.

3 As the saying goes, silence implies
4 consent. PTAC was not created to serve as a
5 forum for stakeholders to convey their ideas and
6 concerns, as you have suggested in your vision
7 statement. Congress created PTAC in order to
8 increase the number of physician-focused APMs.
9 So, if you really want to achieve that goal, I
10 recommend you do two things. First, you should
11 begin providing data and technical assistance
12 that will help stakeholders develop more and
13 better physician-focused APMs. Most of the
14 comment letters you receive ask for this, and you
15 have \$5 million in annual funding to support it.

16 When I served on PTAC, we tried to do
17 this, but HHS lawyers said PTAC had no authority
18 to do anything other than review proposals.
19 Apparently that restriction no longer applies,
20 however, since PTAC has spent the past six months
21 talking about telehealth issues that have nothing
22 to do with actual proposals. If HHS continued to

1 prevent you from providing data and assistance to
2 stakeholders, you need to speak out publicly
3 about the problem.

4 Second, you should ask Congress to
5 change the law so that CMS is required to
6 implement the models that PTAC recommends. Over
7 the past nine months, CMS has implemented many
8 major changes in payments and new Alternative
9 Payment Models. This makes it very clear that
10 the failure to implement the models PTAC has
11 recommended is a lack of willingness by CMS to do
12 so, not a lack of resources or ability. Only
13 Congress can change that, and the members of PTAC
14 need to publicly support that change.

15 CHAIR BAILET: Thank you, Harold. The
16 next public commenter is, Dr. Eitan Sobel.

17 DR. SOBEL: My comments are on the
18 financial aspect and the technology aspect of
19 telehealth. Those ideas are outlined in my PTAC
20 proposal of 2019 and 2020, and I will be happy to
21 explain them in great details outside of this
22 venue. Telehealth could turn out to be very

1 expensive. For years, insurance payers were
2 concerned about overutilization of telehealth
3 delivering high volume of low-value care.
4 Nowadays, the pandemic has made telehealth
5 popular.

6 It is about safety, and therefore,
7 telehealth is here to stay. But it does not have
8 to be a money pit business. Efficient telehealth
9 could deliver great care and dramatically cut
10 costs. So, what is efficient telehealth?
11 Efficient telehealth is done in the setting of a
12 medical team. Everything is one body without
13 duplication of care.

14 For example, physical examination
15 could be performed by one member of the team.
16 Efficient telehealth cuts unnecessary transitions
17 of care and eliminates unnecessary steps of
18 transition. Efficient telehealth allows
19 continuation of care regardless of location, and
20 therefore, team members will provide care after
21 the transition. In essence, condition of care
22 will become in part, continuation of care.

1 It will be efficient and less
2 expensive. The team approach to telehealth
3 requires integrated technology. So, what is
4 integrated technology? Integrated technology
5 provides roads and bridges for information and
6 communication. We have unique opportunity to
7 correct our mistakes of the EMR²³ implementation
8 era. Integrated technology will be owned
9 and shared by all of us and will promote
10 vertical thinking, allowing care of multiple
11 patients, as opposed to the horizontal thinking
12 of the current EMRs.

13 Integrated technology will open the
14 market for competition. Competition reduces
15 monopolism, increases patient choice, promotes
16 better care and efficient care. Integrated
17 technology allows innovative, new coordination of
18 care mechanisms and new payment models. Those
19 ideas are independent of our debate about single
20 payer versus multiple payers.

21 In my PTAC proposal, I speak about

23 Electronic medical record

1 Regional Referral Centers or RRCs as a tool to
2 decrease costs and promote competition, which you
3 are welcome to read about. To summarize,
4 efficient health care and integrated technology
5 could be the keys for better care, enormous cost
6 savings, and avoiding the money pit business of
7 telehealth. Thank you.

8 CHAIR BAILET: Thank you, Dr. Sobel.
9 And finally, we have Dr. Larry Kosinski, the
10 Chief Medical Officer of SonarMD. Larry. Are
11 you with us, Larry?

12 OPERATOR: Make sure you're unmuted,
13 Dr. Kosinski.

14 CHAIR BAILET: Operator, is Larry on
15 the line?

16 OPERATOR: Yes, he doesn't seem to be
17 responding. He's unmuted.

18 * **Closing Remarks**

19 CHAIR BAILET: Okay. All right.
20 Well, I want to thank everyone for participating
21 today, members of the public, as well as my
22 colleagues on the Committee. We explored many

1 different facets of telehealth and also laid down
2 some of the groundwork for future changes to
3 come. You can keep an eye out for the resulting
4 reports and any other announcements by joining
5 the PTAC listserv available at the ASPE PTAC
6 website.

7 I want to thank you all for taking
8 time out of your busy schedule to join us today.
9 Please take care, be well, be safe. And the
10 purpose of today, the meeting is adjourned.

11 (Whereupon, the above-entitled matter
12 went off the record at 11:57 a.m.)

C E R T I F I C A T E

This is to certify that the foregoing transcript


In the matter of: Advisory Committee

Before: PTAC

Date: 12-08-20

Place: virtual meeting

was duly recorded and accurately transcribed under my direction; further, that said transcript is a true and accurate record of the proceedings.



Court Reporter

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701